TODAY'S MARKET INTELLIGENCE
Sinocell: Subsidiary SCTA02A Injection Gets Clinical Trial Approval
English summary
Sinocell announced its controlling subsidiary received approval from the National Medical Products Administration to conduct clinical trials for SCTA02A injection in chronic hepatitis B. The product is a recombinant anti-HBsAg monoclonal antibody, and the phase I trial is approved.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence